Proposal to list urology, ostomy and continence products supplied by Coloplast Pty Ltd

Hospital devices

Consultation Closed

What we’re proposing

PHARMAC is seeking feedback on a proposal to list a range of urology, ostomy and continence products (“UOC Products”) in Part III of Section H of the Pharmaceutical Schedule from 1 December 2018, through a listing agreement with Coloplast Pty Ltd (“Coloplast”).

Consultation closes at 4pm on Tuesday 9 October 2018 and feedback can be emailed to denise.mundy@pharmac.govt.nz.

What would the effect be?

From 1 December 2018, Coloplast’s range of UOC Products would be listed under the proposed national agreement for all DHBs to purchase under, subject to consultation and approval by PHARMAC’s Board or delegate (“Agreement”).

The Agreement would not be for sole supply, with DHBs continuing to be able to purchase other suppliers’ brands of UOC Products.

The Agreement would supersede any existing DHB contracts with Coloplast for the UOC Products included in the Agreement.  Any UOC Products listed in the Agreement and purchased by a DHB would be at the price, terms and conditions stated in the Agreement, effective from the date of listing on the Pharmaceutical Schedule.

As part of the Agreement, Coloplast would provide training and education that would be tailored to the needs of individual DHBs.

Who we think will be interested

  • Suppliers and Wholesalers
  • DHB Staff
    • stoma nurses
    • urology clinicians
    • clinical staff in a range of inpatient, outpatient and community settings where UOC Products are used
    • procurement and supply chain personnel
  • Users of UOC Products provided by DHBs

About UOC products

UOC Products are used in hospital and community settings, from short to long-term use.

Urology products include urethral, suprapubic and sheath catheters, bags and accessories for the management of urinary drainage.

Ostomy products include one and two-piece pouching systems to manage stoma drainage, for example colostomy or urostomy drainage, as well as a range of skin protection products.

Continence products include a range of devices to help manage bowel and bladder control problems, including pads, collection systems and skin protection products, as well as nappies for infants for use while they are in hospital.

Why we’re proposing this

In May 2018 PHARMAC issued a Request for Proposals (“RFP”) for the supply of urology, ostomy and continence products.

The RFP was for non-exclusive national agreements for listing in the Pharmaceutical Schedule.

PHARMAC is working with a range of suppliers to seek provisional agreements and this proposal is the latest to arise from that process.  We expect to consult on further proposed agreements in the urology, ostomy and continence categories over the coming months.

Details about our proposal

PHARMAC has entered into a provisional Agreement with Coloplast for a range of UOC Products.  Pricing has been made available to appropriate DHB personnel.

This proposal would result in listing 740 UOC Products on the Pharmaceutical Schedule.

The brand ranges included in the Agreement are:

Ostomy (555 products)

  • Alterna
  • Brava
  • Coloplast
  • Easiflex
  • Fistula
  • SenSura
  • SenSura Mio

Urology (171 products)

  • Coloplast
  • Conveen
  • EasiCath
  • Foysil
  • Releen
  • Self-Cath
  • Simpla
  • SpeediCath
  • X-Flow

Continence (14 products)

  • Peristeen
  • Conveen

To provide feedback

Send us an email: denise.mundy@pharmac.govt.nz by 4pm Tuesday 9 October 2018.

All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.